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Hepatitis C virus recurrence (wruch is defined by detection ofHCV RNA in serum) 
in post-transplanted liver is universal but the progression of infection remains 
unpredictable, varying from case to case. It has been estimated that 75%-80% of the HCV 
recurrence patients will suffer chromc hepatitis C infection and up to a trurd of them will 
progress into the development of fibrosis and cirrhosis within 5 years post-transplantation. 
Therefore, finding ways to predict early on the progression of fibrosis can contribute to 
better prognoses. Recent literatures have mentioned that the hepatitis C virus relies on the 
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CHAPTER 1 Introduction 
Hepatitis C Virus Infection 
Hepatitis C Virus (HCV) has originally been identified in 1989 as a positive­
stranded RNA flavivirus which according to the World Health Organization infects an 
estimate of 170 million people worldwide (1-3). HCV is known to have a rapid mutation 
rate and is classified into 6 genotypes and over 100 subtypes varying among people (3, 4). 
Majority of HCV -infected Americans who were born between 1945 and 1964 acquired the 
virus through either needle sharing involved in recreational drug use or by blood 
transfusions that were received before 1992 due to the lack of HCV antibody screening. 
Other potential risk factors to HCV infection are long-term hemodialysis and frequent 
blood exposure in health care environments (5, 6). 
HCV is highly persistent and 75% of HCV -infected patients develop chronic liver 
diseases (7,8). Currently there are few therapeutic options such as, combination therapy 
using the cytokine peginterferon-a which is injected subcutaneously once a week and the 
nucleoside analogue ribavirin which is taken orally twice daily to achieve a sustained viral 
response (SVR) as conventional treatment for chronic hepatitis C (CHC) infection. Patients 
with HCV genotype 2 or 3 are known to have about 80% or higher success rates to 
treatment after 12-24 weeks, whereas genotype 1 and 4 have only 50% response rate to 
factors are 
./L.....'...........'u nrPQPnt remams (1 
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1 
The IRES allows ribosome to bind directly onto this region without translation initiation 
factors , assisting in control of translation (18). 
H 
5'-UTR 
3"-UTR 
5' 
Complete HCV genome 
Figure-I: The full-length HCY RNA genome. (Henke, the EMBO Journal 2008) (18). 
HCV 
I~-cell attachmentl @ 
Transport and release 
Hcv·nNA • 
Hcv·nNA 
Hepatocyte 
Figure-2: Life cycle ofHCY. (Sakamoto, Journal of Gastroenterology 2009)(19). 
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Figure-3: Illustration oftbe steps and proteins involved in the process of micro RNA-dependent gene 
regulation. (T. Pietschmann, Journal of Hepatology 2009) (42). 
MicroRNAs and HeV 
Since HeV replication is predominantly located in the liver, the viral life cycle 
appears to be influenced by factors mainly found in the liver cells. There are expression 
patterns of mammalian miRNAs such as miR-122, miR-152, miR-194, miR-199, and miR­
215 which have been discovered or predicted to be located specifically within the liver 
(36). Recent studies have suggested that miR-122 (which is endogenously produced in the 
10 

host cells) playa role in the stimulation of HCV RNA synthesis in liver cells and in the 
cultured human hepatoma Huh7 cells (1, 2,18,40,43-45). MiR-122 is known to be 
abundantly made in the liver where it makes up about 70% of the total miRNA population 
and it is transcribed from the non-coding polyadenylated RNA transcript ofthe CCHCRI 
gene (coiled-coil alpha-helical rod protein I) which is thought to be a regulator in liver 
development (I, 2). Through bioinformatics, miR-122 is predicted to target hundreds of 
different mRNAs and its' regulatory roles are still being investigated (41). 
In relations to miR-122 and HCV, prior experiment of mutagenesis has suggested 
that miR-122 binds to two sites on the 5'-UTR ofHCV RNA, located upstream of the 
HCV IRES (2). These two sites lie next to each other with a short spacer in between them 
and the complementary matching ofmiR-122 to these binding sites, which is conserved 
among all six HCV genotypes, demonstrated a positive effect on the viral replication (2). 
High levels ofmiR-122 portrayed an accumulation ofHCV translation while at low levels 
ofmiR-122, (which were achieved through antisense oligonucleotides) it resulted in an 
80% decreased production of viral RNA genome in the liver cell lines Huh7 (2, 18). 
However, there was another study performed in which they gathered their data from liver 
biopsies of patients with CHC undergoing treatment and their findings suggested no 
positive association between HCV RNA levels and miR-122 (45). The role ofmiR-122 on 
the replication ofHCV may have demonstrated more strongly in vitro compared to in vivo 
experiments but either way, conclusions drawn from in vitro studies should be carefully 
analyzed before assuming it as fact for in vivo applications (45). 
II 
There are other reports stating a group of cellular miRNAs, (miR-196, miR-296, 
miR-351, miR-431, and miR-448) when triggered by interferon, behaved as inhibitors of 
Hev replication. These miRNAs displayed almost a perfect match on the HeV RNA 
genome and actively lowered mRNA of Hev by 80% (44). Another recent study used a 
miRNA target search algorithm to identify miR-199a* having complementarity to the 
Hev genome in domain II of the IRES region in the 5'-UTR (46). They discovered that 
miR-199a* behaved like a RNA silencer and overexpression of this miR-199a* inhibited 
Hev replication, regardless of the Hev genotype. The suppression was irreversible by 
either mutation in the miR-199a* sequence or in its' target sequence in the Hev (46). 
These findings illustrate the versatile functions ofmiRNAs in the role of HeV.Some are 
known to enhance replication of Hev whereas others are known to inhibit the virus. The 
exact biological pathway in the involvement between these certain miRNAs and HeV 
however, still remains unknown. 
n/TR 3 UlR 
~ 
-v­
rniR-122 m iR-199a 
Figure-4: Schematic diagram of the HCY genome. The target sites for miRNAs known to regulate 
HCY RNA replication. (T. Pietschmann, Journal of Hepatology 2009) (42) 
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10 
Liver specimens. Total RNA was isolated from formalin-fixed paraffin-embedded 
(FFPE) liver biopsies using RecoverAllTM Total Nucleic Acid Isolation Kit (Ambion). 
Ambion® recommended using slices that are at least 1 0 ~m thick in order to risk miRNA 
loss because anything thinner than 1 0 ~m would cause cells to split open and jf cytoplasm 
is revealed, miRNA can be washed away during the deparaffinization washing step. To 
determine how many tissue slices should be cut per sample, a test set of samples were 
sectioned into 2 slices and 4 slices. We wanted to observe which slices would be most 
efficient in extracting the most RNA out of the samples without clogging the filter from 
too much paraffin. After noticing that the 4 slices did not overwhelm the filters, we 
decided to increase it to 5 slices in order to maximize the collection of RNA for all the 
samples. The sectioning of the liver biopsies that were embedded in the paraffin blocks 
were performed by VCU Molecular Diagnostics (MDx). 
RNA isolation. RNA isolation was performed using the Applied Biosystems (AB) 
RecoverAllTM Total Nucleic Acid Isolation Kit - Optimized for FFPE (paraformaldehyde­
fixed, paraffin-embedded) samples/tissues. [Part Number AM1975] © 2008 Ambion, Inc., 
in accordance with the manufacturer's protocol. This kit was chosen for the study because 
it is specifically designed to extract total nucleic acids (RNA, miRNA, and DNA) from 
FFPE tissues and according to its' manufacturer, the recovered products are suitable for 
quantitative real-time RT-PCR. 
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Extension of prim...r on miRNA 
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3 ' :::::) Loop;;d 
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3 ' :::::) 5 
Figure-5: Reverse Transcription Step (TaqMan MicroRNA Assays Protocol 2006) (59) 
TaqMan RT-PCR (Real Time - Polymerase Chain Reaction) was carried out for the 
amplification step of the PCR products from the cDNA, using the TaqMan MicroRNA 
Assay and the TaqMan® Universal Master Mix without AmpErase UNO (uracil-N­
glycosylase). The purpose of UNO is to prevent PCR carryover products by hydrolyzing 
any uracil-glycosidic bonds to block DNA polymerase replication. However, due to our 
RNA samples being fragmented and degraded from the FFPE process and being aged, it 
was decided to exclude the AmpErase UNO from the Master Mix so we could maximize 
what little RNA that remained in our samples. 2.4, ..d of the diluted RT products was added 
to the 17.6J..lI of the reaction mixtures. The ABI Prism 7700 Sequence Detector was set at 
conditions of 95°C for 10 minutes (denaturation step), 92°C for 15 seconds (annealing 
step), and 60°C for 60 seconds (extension step) which was repeated for 40 cycles. The 
amplifications for miR-122 were performed in duplicates while the endogenous control 
RNU 44 was performed in single reaction. 
What makes this assay robust from any other PCR is that TaqMan uses a sequence 
specific probe that anneals to the complementary sequence ofthe interested target site. The 
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Figure-6: The peR Step (TaqMan MicroRNA Assays Protocol 2006) (59) 
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The results portrayed amplification curves and the Critical Threshold (Ct) values 
for each reaction. The duplicate Ct values for each sample were averaged. No template 
controls (NTC) were also included in each run to ensure no false-positive had occurred. 
The Ct value of the miR-122 was subtracted from the Ct value of the RNU 44 to give the 
first ~Ct value. Delta-delta calculations were carried out to evaluate the fold change 
between the control group and the group of interest. 
Gene expression studies 
A list of237 differentially expressed genes (DEG) (bead-types with a false 
discovery rate (FDR<10%) were considered significant genes) within selected RNA 
samples was obtained from a previously performed Illurnina reaction when gene 
expression profiles were evaluated for the same patient group (51). The list of DEG was 
then compared to the lists of predicted gene targets of miR -122 that were gathered from 
three different database sources: MIRANDA, PicTar, and Target Scan. In accordance to 
the three databases, there were 40 genes in the DEG list that were found to be predicted 
targets ofmiR-122. The 40 DEG were further narrowed down to their functions, 
particularly focusing on those genes involving in fibrosis progression, matrix deposition 
and production, apoptosis and/or immune response. BCAP31 [B-cell receptor-associated 
protein 31] was selected to test out its expression in our samples. The gene CD4 was also 
added into the study because of its' important involvement in immune response against 
HCY. Studies have found that HCY recurrent infection may possibly behave in a similar 
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manner as acute HCV infection, suggesting the need for a strong and long-lasting effect of 
CD4+ T cell response for clearance and control of the virus (60). Defect in the cellular 
immune response has been associated with HCV persistence, leading to chronic infection 
(61). 
TaqMan® Gene Expression Master Mix along with the TaqMan Gene Expression 
Assays was used following the manufacturer's protocol to detect and quantify BCAP31 
and CD4 in the RNA samples. All the RNA samples were calculated and diluted to 8ng/1l1 
and151l1 of the normalized RNA was then aliquotted into 35111 ofthe reaction mixtures. 
Reverse transcription (RT) was carried out in the GeneAmp® PCR System 9700 at 
conditions set to 25°C for 10 minutes (incubation period for efficient primer-RNA 
template binding), 48°C for 30 minutes (reverse transcriptase activity), 95°C for 5 minutes 
(reverse transcriptase inactivation period), and held at 4°C for infinity using TaqMan® 
Reverse Transcription Reagents and random hexamers as the primers for conversion of 
total RNA into cDNA. 
lExtensie·n of primer on mANA s·___~·--"'._"",--~·--·-, _.....-----..........---.-..........___~ mRNt-. 
RT '" &' eDNA R' f'o:leO'.Step Potm:;r Synthesis of 1 st eDNA strand ~t 5' eDNA 
Figure-7: Reverse Transcription Step (TaqMan® Gene Expression Master Mix 2007) (62) 
TaqMan RT-PCR (Real Time - Polymerase Chain Reaction) was performed next to 
amplify the PCR products from the cDNA by using the TaqMan® Universal Master Mix 
without AmpErase UNG along with the TaqMan® Pre-Developed Assay Reagents 
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Figure-8: Chemistry Overview of 5' Nuclease Assay (TaqMan® Gene Expression Master Mix 2007) (62) 
28 

Beta-2-microglobulin (B2M) was selected as the housekeeping gene for the study 
because a test set demonstrated favorable Ct value in the FFPE samples compared to 
glucuronidase-beta (GUSB) which is another housekeeping gene that was reconunended as 
a suitable reference gene for analyzing liver tissue infected with chronic hepatitis (63). 
GUSB and B2M were tested on four RNA isolations, two from FFPE samples and two 
from frozen liver tissues. The Ct values suggested GUSB would work well as the 
housekeeping gene for analysis of RNA from frozen tissues however, for the FFPE 
samples, B2M was the better choice because of the lower Ct value, implying better 
amplification (Table}). 
Table 1. Ct Values for the Two Housekeeping Genes: 
Sample # GUSB B2M 
Frozen Liver Samples: 0-587 25.14 22.13 
0-597 25.35 
33.73 
23.26 
29.10FFPE Liver Samples: 5512 
15818 34.88 30.18 I 
PCR was carried out in 20111 reaction mixtures in the ABI Prism 7700 Sequence 
Detector at conditions set to 95°C for} 0 minutes (denaturation step), 92°C for 15 seconds 
(annealing step), and 60°C for 60 seconds ( extension step) which was repeated for 40 
cycles. All amplifications for the genes of interest were carried out in duplicate reactions, 
along with a single reaction of the endogenous control B2M beside each run. The levels of 
B2M mRNA were used as the endogenous reference for normalization to quantify 
BCAP3} and CD4. No template control (NTC) was run with every reaction to ensure 
proper assay function. 
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Table-2. Cbaracteristics of Liver Transplant Recipients 
Group 1 Group 2 Group 3 
51 ±8 
69 
J~ 
l! 
53 ±9 
43 
Jl 
If 
56 ±7 
62 
Virus genotype 
(% Genotype 1) 
HCC (% present) _ 
-
II 
il 
84 
17 
JL 
II 
94 
13 
~L 57 _Jl 
-11 29 -r 
100 
15 
Donor Type 
(% Deceased Donors) .II 79 II 81 87 II 69 
Immunosuppressant drugs 
Gender (% males) II 58 II 
II 
(% CsA) 
.11 67 ~L 56 _JL 64 Jl 85 
'I -
57Treated acute rejection (%) If 44 II 31 Ir ,r- 46 
Follow-up period post-
transplantation (years) 8.3 ± 2.6 9.6 ± 2.5 7.6 ± 2.5 I 7.5 ± 2.4 
Mean time of HCVrec (months) 5.0 ±3.8 5.6 ±4.8 5.7 ±3.7 3.7±1.9 
MiR-122 Expression 
The differential expression of miR-122 between normal livers from normal liver 
donors versus cirrhotic livers from patients with CHC infection was first evaluated. Two 
sample t-tests were performed to evaluate the expression ofmiR-122 within normal livers 
compared to non-transplanted (non-TX), HCV infected cirrhotic livers [Figure 9]. Each 
sample contained a miR-122 Ct value and an endogenous control RNU 44 Ct value. The 
6Ct values, which is equivalent to the difference in threshold cycles for target and 
reference (Ct,x - Ct,R) for normalizing the expression miR-122 were analyzed. The t-tests 
value of P= 0.0006 showed significant differential expression between the two groups. 
T:l~Ct calculations were carried out to demonstrate relative fold changes in miR -122 
expression (which were initially normalized to the endogenous reference gene RNU 44) 
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Figure - 9. Comparing the miR-122 ~Ct values between normal liver samples and in HCY infected 
liver samples that were not transplanted. 
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Figure-tO. Dilution Slopes for miR-122 and RNU 44 using the 1:5 serial dilutions. 
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MiR-122 Expression in Post-TX Livers 
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Figure - 11. Delta Ct values ofmiR-122 in HCV recurrence groups. 
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ANOVA Results 
A 
Comparisons significant at the 0.05 level are indicated by -*. 
Recurrence 
Comparison 
Difference 
Between 
Means 
Simultaneous 95% Confidence 
Limits 
Group 3 (Severe) ­
Group 1 (Benign) 
7.324 
I 
-6.416 21 .064 
Group 3 (Severe) ­
Group 2 (Intermediate) 
9.726 -4.447 23.899 
Group 1 (Benign) ­
Group 2 (Intermediate) 
2.402 -11 .065 15.869 
B 

Comparisons significant at the 0.05 level are indicated by ***. 
Recurrence 
Comparison 
Difference 
Between 
Means 
Simultaneous 95% Confidence 
Limits 
Group 3 (Severe) ­
Group 1 (Benign) 
-2.493 -12.400 7.414 
Group 3 (Severe) ­
Group 2 (Intermediate) 
-3 .838 -14 .062 6.386 
Group 1 (Benign)­
Group 2 (Intermediate) 
-1 .344 -10.801 8.113 
Table 3. Comparison of the outcome variable t.ct miR-122 within groups: (A) at time ofHCV 
recurrence and (8) at 3 years post-TX. 
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MiR-l22 and Viral load 
To observe for any correlation between the level of miR-122 expression and the 
amount of virus in the bloodstream (viremia), a Pearson's Correlation Analysis was 
applied to the data. The results in [Table 4] suggested a positive correlation in Group 3 
(Severe) at time of HCVrec. 
TABLE 4. Pearson's Correlation Coefficient Values for miR-122 and Viremia 
Recurrence group levels Pearson Correlation Coefficients(* denotes a significant correlation) 
Time of HCY recurrence Three years post treatment 
Group 1 (Benign) 0.03 0.08 
Group 2 (Intermediate) -0.35 0.41 
Group 3 (Severe) 0.58* -0.37 
HCAP3l Expression 
To investigate the expression patterns of BCAP31 among the severity groups, the 
student t-tests on the mean ~Ct values between Group 1 (Benign) and Group 3 (Severe) at 
each time point were carried out. There were no significance found in the level of BCAP31 
expression among the two groups (P= 0.49 at time of recurrence, p= 0.09 at 3 years post-
TX) [Figure 12]. Delta-delta calculations were also performed to evaluate the relative fold 
changes in the expression of BCAP31 (which have been normalized to the endogenous 
housekeeping gene B2M) between the control group (normal livers) and Group 1 (Benign) 
and 3 (Severe) independently. There were no significant patterns of BCAP3l expression 
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among the groups. Amplification efficiencies for BCAP31 and B2M using the 1:5 serial 
dilutions had slopes of -3.80 and -3.47 respectively [Figure 13]. 
BCAP31 Expression in Post-TX Livers 
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Figure - 12. Delta Ct values of BCAP31 in HCY recurrence groups. 
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BCAP31 and miR-122 Expression 
Since BCAP3l was an in silico predicted target of miR-122, we wanted to observe 
for any correlation between the expression of BCAP31 and the expression of miR-122 
within each group at each time point. We used Pearson's correlation coefficient and found 
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that there is one significant correlation between BCAP31 and miR -122 only at the time of 
HCVrec in Group 3 (Severe). It appears to have a negative relationship. The rest ofthe 
groups had no significant correlations at either time points. 
TABLE 5. Pearson's Correlation Coefficient Values for miR-122 and BCAP31 
Recurrence group levels Pearson Correlation Coeffi
Time of HCY recurrence 
cients(* denotes a significant correlation) 
Three years post treatment 
Group 1 (Benign) 0.32 -0.20 
Group 2 (Intermediate) -0.14 0.07 
Group 3 (Severe) -0.56* 0.22 
CD4 Expression 
To evaluate the expression of CD4 in regards to cirrhotic fibrosis, t-tests were done 
on the mean value of ~Ct between the normal liver samples (6.69) and the non-TX HCV 
infected cirrhotic liver samples (6.95). The student t-tests value of P= 0.669 suggested no 
significance [Figure 14]. 
To observe the role of host cellular specific immune response in the progression of 
HCVrec, we evaluated the CD4 expression at time of HCVrec. The student t-tests revealed 
p= 0.053, suggesting differential expression of the mean ~Ct values between Group 1 
(Benign) and Group 3 (Severe) at time of HCVrec being statistically significant [Figure 
15]. 
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Figure - 14. Comparing the CD4 DoCt values between normal liver samples and in liver cirrhotic 
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